PT-141 / Bremelanotide — Half-Life, Dosing & Protocol Guide

Also known as: Vyleesi, Bremelanotide, PT141

FDA-Approved· Half-life from FDA NDA 210557 (Vyleesi)

Plasma Half-Life

~2.7 hours SC

Source: FDA NDA 210557 (Vyleesi)

Route

Subcutaneous autoinjector

Frequency

On-demand

Standard Dose

1.75mg SC PRN ≥45 min before activity

Pharmacokinetics & Mechanism

Bremelanotide (PT-141, Vyleesi) has a mean terminal half-life of approximately 2.7 hours (range 1.9–4.0 hours) after subcutaneous injection, per the FDA Vyleesi prescribing label (NDA 210557, approved 2019). It is a cyclic heptapeptide melanocortin agonist acting at MC4R in the CNS to modulate sexual desire. Contraindicated in cardiovascular disease; can raise blood pressure ~5 mmHg peak at 4 hours.

Track PT-141 / Bremelanotide in Halflife

The Halflife app tracks your PT-141 / Bremelanotide protocol with real-time concentration curves, dose logging, injection site rotation, and vial inventory — all on-device with no account required.

See your PT-141 / Bremelanotide curve live

Real-time concentration model based on your actual dose and injection time. Free iOS app.

Download on App Store